Medibact GuidesShop at Medibact

Stacking Module

TB-500 Stacking Module

TB-500 is almost never discussed alone — it appears in all three named repair blends and is the compound most often paired with BPC-157. Two things make its stacking picture distinctive: it is dosed on a different scale from most of its partners, and it is one of the most frequently mislabelled peptides on the research market, which makes verification a stacking concern rather than just a sourcing one.

TB-500 Guide at MedibactTB-500 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking TB-500

  • TB-500 is dosed in milligrams while BPC-157, its most common partner, is dosed in micrograms. This is the single most common source of arithmetic error in repair stacks — never carry a unit count between them.
  • It is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of the 43-amino-acid Thymosin Beta-4 protein, and the two are widely conflated by vendors. A mass-spec COA is the only way to know which you have, and it matters because the reported dosing scales differ.
  • Reported dosing frequency is lower than BPC-157's — commonly described as twice weekly rather than daily — so in a concurrent stack the two are not on the same schedule.
  • No controlled trial has studied TB-500 combined with anything, and human data on the compound alone are limited.

Combinations in detail

Wolverine

TB-500 + BPC-157
Why it is proposed
The canonical pairing. TB-500's studied role in actin regulation and cell migration is presented as the mobilisation half of repair, with BPC-157's angiogenesis and tissue-healing literature as the other half.
What is reported in practice
Run concurrently on different schedules — TB-500 less frequently, on a milligram scale; BPC-157 more frequently, in micrograms. Community protocols describe a defined block of weeks with a break rather than open-ended use.
Cautions specific to this combination
Beyond the scale difference, the mislabelling problem compounds here: if a vial labelled TB-500 actually contains full-length Thymosin Beta-4, a protocol written for the fragment does not apply to it.

GLOW

TB-500 + BPC-157 + GHK-Cu
Why it is proposed
Adds copper-peptide matrix remodeling to the repair pairing, shifting the stated focus toward skin and connective tissue alongside soft-tissue recovery.
What is reported in practice
Predominantly a pre-mixed blend vial, administered as a single draw that fixes all three components in a set ratio.
Cautions specific to this combination
In a blend, TB-500's milligram scale and GHK-Cu's differ again from BPC-157's micrograms, so the split matters more here than in a two-component stack — and the split is not standardised.

KLOW

TB-500 + BPC-157 + GHK-Cu + KPV
Why it is proposed
The four-component version, adding KPV's anti-inflammatory signaling on top of GLOW's repair-plus-remodeling premise.
What is reported in practice
Sold as a single 80 mg blend vial. One draw delivers a fixed ratio of four compounds; none can be adjusted independently.
Cautions specific to this combination
Four unapproved compounds with no combination data and vendor-variable splits. The confidence of the marketing around this blend is not matched by its evidence base.

Immune-adjacent pairing

TB-500 + Thymosin Alpha-1
Why it is proposed
Occasionally discussed because both derive from thymic peptide biology, though they act on different things — Thymosin Alpha-1 is studied for immune modulation rather than tissue repair.
What is reported in practice
Reported as separate vials; this is a much less common pairing than the repair blends and has correspondingly less reported practice behind it.
Cautions specific to this combination
Shared origin in thymic biology is a weak basis for combining — the mechanisms studied are genuinely different. Treat this as a thinly-reported pairing rather than an established one.

What to avoid, and why

  • Assuming a vial labelled TB-500 contains the fragment rather than full-length Thymosin Beta-4 without a mass-spec COA — the compounds differ and so do their reported scales.
  • Applying BPC-157's dosing frequency or unit counts to TB-500. Different scale, different reported interval.
  • Adding a second thymosin-derived compound expecting additive repair effects; the reported rationale for the named blends is mechanistic diversity, not more of the same.

If you are using a pre-mixed blend

Because this compound is sold inside pre-mixed blend vials as well as on its own, one more arithmetic point matters: a blend label's milligram figure is the combined mass of all its components, and vendors do not standardise the per-component split. You cannot derive any single component's concentration from the blend total, and a volume figure that applied to one vendor's vial does not transfer to another's. Separate vials remove that ambiguity entirely, at the cost of more injections.

Related reading

Wolverine — BPC-157 + TB-500GLOW — BPC-157 + TB-500 + GHK-CuKLOW — BPC-157 + TB-500 + GHK-Cu + KPVThe Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.